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Intracellular scaffold proteins interact with kinases and other signaling molecules to control signal transduction [11] [12] [13] . IQGAP1 is a scaffold that is known to interact with RAF, MEK1/2 and ERK1/2 MAPK cascade kinases, as well as with a host of other proteins 9, 10, 15 . Some studies have suggested a role for IQGAP1 in enhancing tumorigenesis [16] [17] [18] [19] , but Iqgap1 knockout mice are viable and fertile 20 , do not show any defects in normal epithelium and heal wounds normally (Supplementary Fig. 1 ). Thus, IQGAP1 is a potential tumor-required scaffold protein that is dispensable for homeostasis.
To further explore this possibility functionally, we examined the susceptibility of Iqgap1-null mice to tumor formation in a model of RAS-driven cancer. We observed that Iqgap1 knockout mice were resistant to Hras-driven chemical carcinogenesis 21 (Fig. 1a,b and Supplementary Fig. 2 ). Iqgap1 heterozygotes showed an intermediate phenotype, suggesting an Iqgap1 gene-dosage effect on tumor susceptibility ( Fig. 1) . Iqgap1 knockout mice also had a sixfold reduction in premalignant epidermal hyperplasia in response to acute Ras-MAPK induction 22 ( Supplementary Fig. 3 ). Expression profiling of the skin of these mice demonstrated that Iqgap1 is required for Ras-driven induction of genes enriched in cellular metabolism Gene Ontology terms ( Supplementary Fig. 4 ) that are characteristic of early Ras-MAPK-driven tumorigenesis 23 . Iqgap1 knockout mice did not differ substantially from wild-type mice in the expression of known Iqgap1 binding partners, suggesting that Iqgap1 is not required for their expression (Supplementary Table 1) .
We then assessed IQGAP1 expression in spontaneous human epidermal cancers to examine the corresponding human skin cancer. IQGAP1 protein was strongly expressed in 45% of human squamous cell carcinomas (n = 60) ( Supplementary Fig. 5 ), consistent with reports in other cancers 24, 25 . In a mouse model 26 of human KRASdriven pancreatic ductal adenocarcinoma 27 , we found that the amount of Iqgap1 protein is increased in pre-neoplasms and advanced tumors (Supplementary Fig. 6 ). To further explore the effects of IQGAP1 in human tissue, we depleted IQGAP1 in RAS-driven organotypic human epidermal neoplasia 28 , a setting that reflects corresponding human cancers, and found that IQGAP1 depletion impaired basement membrane degradation and neoplastic invasion (Fig. 2a) . Similarly to in mice, IQGAP1-deficient human epidermis was normal, in contrast to the severe hypoplasia seen in ERK1/2-deficient tissue (Supplementary Fig. 7 ). Although hypoplasia induced by loss of ERK1/2 has been shown to be associated with reduced cyclin B1 and c-Fos expression leading to G2/M arrest 4 , their expression remains unchanged with IQGAP1 loss. Total ERK1/2 depletion led to hypoplastic tissue collapse in RAS-driven organotypic neoplasia, whereas depletion of IQGAP1 preserved tissue morphology (Fig. 2b) . Although both total and activated phosphorylated ERK1/2 (pERK1/2) were absent in ERK1/2-depleted tissue, IQGAP1-deficient tissue retained some pERK1/2, indicating that IQGAP1 loss down-regulates pERK1/2 but does not eliminate it (Fig. 2b) , an effect that is rescued by IQGAP1 re-expression (Supplementary Fig. 8 ). Further, IQGAP1 depletion diminished downstream ERK1/2 cascade activity (Supplementary Fig. 9 ). IQGAP1 depletion thus lowers the amounts of active ERK1/2 and impedes neoplasia without inducing tissue catastrophe.
The effects of IQGAP1 on pERK1/2 suggested that the anti-neoplastic effects of IQGAP1 loss may occur through alterations in ERK1/2. IQGAP1 binds ERK1/2 through its highly conserved WW domain (Fig. 2c) . Although other IQGAP1 domains are known to bind multiple partners in other signaling pathways 15 , ERK1/2 are the only known proteins that have been confirmed to bind the IQGAP1 WW sequence 14 . Moreover, WW-deleted IQGAP1 mutants do not rescue IQGAP1-mediated effects on pERK1/2 29 . Similarly to scaffold loss, increased scaffold concentrations can also alter signaling pathways by titrating binding partners away from one another 12, 13 , and both overexpression and knockdown of IQGAP1 show similar effects on signal transduction 29 . We therefore used the ERK1/2-binding WW sequence as an approach to target IQGAP1-ERK1/2 interactions. Similarly to IQGAP1 depletion, lentiviral expression of a Myc-tagged WW sequence inhibited neoplastic invasion in organotypic neoplasia (Fig. 2d,e and Supplementary Figs. 8 and 9) . Substitution of two conserved WW-domain tyrosines to alanine (Fig. 2c) abolished this effect (Fig. 2d,e and Supplementary Fig. 8) .
To characterize the action of the IQGAP1 WW domain in additional cancer cell types, we delivered it by lentivirus to cancer cell lines with mutational RAS-MAPK pathway activation (MDA-MB-468, HCT-116 and COLO-829), as well as to cancer cell lines with a wild-type MAPK module (T-47D, COLO-320DM and CHL-1) ( Supplementary  Fig. 10a,b) . The WW domain markedly impaired the proliferation of breast, colorectal and melanoma tumor cells characterized by EGFR overexpression, KRAS mutation and BRAF mutation, respectively, without affecting wild-type MAPK lines ( Supplementary Fig. 10c,d) . Moreover, the WW domain impaired migration of the MAPK mutant lines with no effect on wild-type lines ( Supplementary Fig. 10e-h ). We did not find any changes in IQGAP1, IQGAP2 or IQGAP3 expression levels in these cells (Supplementary Fig. 11 ). To further explore selectivity, we used melanoma cancer cell lines previously characterized to express either the BRAF V600E or NRAS Q61L mutant (COLO-829 and MM-485, respectively), as well as a control melanoma line with wild-type BRAF and NRAS (CHL-1). IQGAP1 WW domain delivery impaired tumorigenesis in the BRAF-and NRAS-mutant cells but not in RAS-MAPK wild-type tumor cells ( Supplementary Fig. 12 ), again suggesting a selective inhibitory effect on neoplasias characterized by mutations upstream of ERK1/2 in the RAS-MAPK pathway. We then performed intratumoral lentiviral injection to determine whether the WW domain can act on established tumors. Subcutaneous tumors derived from human MAPK-mutant breast and melanoma skin cancer cell lines (MDA-MB-468 and COLO-829, respectively) treated with WW lentivirus ceased to grow, whereas control lentivector-injected tumors continued to expand (Supplementary Fig. 13 ). The IQGAP1 WW sequence thus exerts anti-neoplastic effects on not only MAPK pathway-mutant early stage tumors but also established tumors.
To test the antitumor activity of the IQGAP1 WW peptide itself, we rendered the 32-residue WW peptide cell and tissue penetrating by adding eight arginine residues in an approach that mimics HIV TAT sequence function 30 . WW peptide, but not scrambled peptide control, abolished neoplastic invasion in RAS-driven organotypic neoplasia (Fig. 3a) . The WW peptide reduced the amounts of pERK1/2 in oncogenic RAS-transformed keratinocytes and MAPK-mutant cancer cell lines (Supplementary Fig. 14) and impaired the growth of human pancreatic cancer cell lines characterized by mutant KRAS (Supplementary Fig. 15 ). Further, systemic WW peptide delivery by osmotic pump impaired tumorigenesis in mice bearing SK-Mel-28 melanoma tumors, as well as those bearing MDA-MB-468 breast tumors (Supplementary Fig. 16 ). We did not find any morbidity or substantial laboratory abnormalities in WW peptide-treated mice (Supplementary Table 2) .
We next treated Ptf1a +/Cre ; Kras +/G12D ; Trp53 flox/flox mutant mice, which develop lethal pancreatic cancer 26 , with the WW peptide starting at 35 days of age, when palpable tumor mass was present. Compared to treatment with scrambled peptide or gemcitabine, which is commonly used in human pancreatic cancer, WW treatment significantly extended lifespan (Fig. 3b,c and Supplementary  Table 3 ). Visual and histopathological analysis indicated that although WW-treated mice eventually die from pancreatic tumors, Figure 2 The ERK-binding npg these tumors show reduced amounts of pERK1/2, suggesting that the WW peptide sustains inactivation of the Ras-MAPK pathway (Fig. 3d,e and Supplementary Fig. 17) . Thus, systemically delivered Iqgap1 WW peptide shows marked antitumor activity without detectable toxicity. The newly available kinase inhibitor vemurafenib (PLX-4032) targets mutant BRAF V600E MAP3K in melanoma; however, its longterm effectiveness has been hindered by acquired resistance through bypass mechanisms that can restore ERK1/2 activation 2, 5, 6, 8 . If the WW domain acts in a mechanistically distinct fashion from direct kinase inhibition, then the effects of the WW peptide should be unaltered by acquired resistance to BRAF inhibition. We therefore compared the impact of the WW peptide on PLX-4032-sensitive and -resistant melanoma lines. Three PLX-4032-sensitive BRAF V600E -expressing parental human melanoma cancer cell lines, which are all sensitive to the WW peptide ( Fig. 4a,b ; COLO-829, SK-Mel-28 and A375), were rendered resistant to PLX-4032 as described 5, 6 . Resistance of the resulting subclones to PLX-4032-mediated growth inhibition (Fig. 4c,d ) was accompanied by alterations that have been previously associated with the emergence of PLX-4032 resistance 5, 6 , including alterations of insulin-like growth factor 1 receptor (IGF1-R), platelet-derived growth factor receptor-β (PDGFR-β), NRAS and COT (also called MAP3K8) (Supplementary Fig. 18) . In all cases, the WW peptide inhibited the growth of PLX-4032-resistant melanoma subclones (Fig. 4c) similarly to in PLX-4032-sensitive parental cells (Fig. 4a) , indicating that the WW domain acts in a non-redundant fashion to direct kinase inhibition.
To further explore the mechanism of WW peptide action, we next characterized its effects on IQGAP1-ERK binding in primary melanocytes and BRAF V600E -expressing human melanoma cancer cells. The WW peptide substantially decreased the amounts of total ERK1/2 bound to IQGAP1 in cancer cells (Fig. 4e,f) . Notably, very little ERK1/2 was associated with IQGAP1 in primary cells, whereas there was much more ERK1/2 bound to IQGAP1 in cancer cells (Fig. 4e,f and Supplementary Fig. 19 ). The IQGAP1 WW sequence thus blocks scaffold-kinase interactions between IQGAP1 and ERK1/2.
Here we show that the IQGAP1 scaffold is required for tumorigenesis but is dispensable for homeostasis and the IQGAP1 WW sequence blocks neoplasia without inducing the tissue collapse accompanying ERK1/2 ablation. We also present a working model of the resulting scaffold-kinase interaction blockade (SKIB) in cancer (Fig. 4g) . The WW peptide inhibited tumorigenesis in cells from diverse tissues, all of which were characterized by RAS-MAPK pathway activation at a variety of pathway levels, ranging from upstream receptor tyrosine kinases to commonly mutated RAS and RAF genes. Exogenous WW peptide bypassed acquired resistance to vemurafenib (PLX-4032) 5, 6 , a recently approved treatment of BRAF V600E melanoma, suggesting that this approach may be explored in tumors with acquired resistance to RAS-MAPK pathway-targeted drugs. Systemic delivery of a tissuepenetrating Iqgap1 WW peptide impaired growth of established tumors and increased the lifespan of tumor-bearing mice without detectable toxicity. These data support future efforts at therapeutic targeting of scaffold-kinase interactions as a tumor-selective strategy to inhibit oncogenic signaling in cancer.
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